Lonza Capital Markets Day: Pure-Play CDMO Transformation Complete, Mid-Term Model Upgraded to Low-Teens Growth and High-Thirties CORE EBITDA Margin

On October 14, Lonza held its Capital Markets Day in Vacaville, California, declaring its pure-play CDMO transformation complete in under two years and upgrading its Organic Growth Model: low-teens (10–13%) organic CER sales growth over time, a mid-term CORE EBITDA margin ambition raised to the high thirties, and ROIC of 2–3x WACC. Q3 2026 performed in line across all platforms and full-year guidance (11–12% CER growth, 33–34% margin) was reiterated.

On October 14, Swiss CDMO giant Lonza held its 2026 Capital Markets Day at its Vacaville, California site, declaring that the pure-play CDMO transformation under its 'One Lonza' strategy is formally complete, and upgrading its Organic Growth Model on the back of stronger operational and financial performance. It is the company's first systematic presentation of its long-term financial blueprint for the 'pure CDMO' era since the CHF 2.3B sale of its Capsules & Health Ingredients (CHI) business to Lone Star in March.

From slimming down to focusing: a pure-play CDMO in under two years

Lonza states that, with the exit of the CHI business and a series of further divestments, it completed its transformation into a focused pure-play CDMO in less than two years. The company now concentrates on four business platforms — Integrated Biologics, Advanced Synthesis (small molecules and bioconjugates), Drug Product, and Cell & Gene — delivering a more integrated end-to-end offering to clients. The CMD venue itself is symbolic: the Vacaville site, acquired from Roche in 2024, is Lonza's largest Integrated Biologics site and a core pillar of its commercial biologics capacity.

The upgraded model: growth, margin and capital returns all moving up

The upgraded Organic Growth Model contains four core pillars: first, low-teens (10–13%) organic CER sales growth on average over time; second, CORE EBITDA growing ahead of sales, with the mid-term CORE EBITDA margin ambition upgraded to the high thirties; third, a new mid-term ROIC ambition of two to three times today's WACC; and fourth, improving free-cash-flow conversion (FCF/EBITDA) on average over time. Organic CapEx is expected to fluctuate around the mid-to-high teens as a percentage of sales, alongside a progressive dividend policy.

Q3 in line, full-year guidance reiterated: another footnote to a global outsourcing upcycle

Lonza reported that Q3 2026 performance was in line with expectations across all business platforms, and reiterated its upgraded full-year 2026 guidance: 11–12% CER sales growth and a CORE EBITDA margin of 33–34%, with an FX headwind of roughly 2–3% on sales growth. Q3 performance of the divested CHI business was also in line, with mid-single-digit CER growth expected for the full year. CEO Wolfgang Wienand noted: 'The transformation into a pure-play CDMO has created a stronger, more integrated global organization that is delivering for our customers across all business platforms.'

Lonza performed well in Q3 2026 and we continued to successfully execute our One Lonza Strategy. The transformation into a pure-play CDMO has created a stronger, more integrated global organization that is delivering for our customers across all business platforms.

Editorial view: Western refocusing and Chinese expansion converge on the same upcycle

Placing Lonza's Capital Markets Day in a global context makes the signal even clearer. Since H2 2026, CXO sentiment has been recovering in sync worldwide: China's leading CXOs posted collectively accelerating order growth (WuXi AppTec backlog +25.2%, Asymchem +54%, Pharmaron +30%), Samsung Biologics surpassed US$22B in cumulative orders, and Lonza now presents a mid-term blueprint built on the Western path of 'refocus + margin repair'. Divesting non-core assets (Lonza's CHI exit) and counter-cyclically acquiring capacity (WuXi's M&A, Samsung's plant builds) point in opposite tactical directions but rest on the same judgment — outsourcing penetration keeps climbing, and top-tier capacity plus complex-molecule platforms will be the scarce resources of the next competitive cycle. For sponsors, 'who to pick as the capacity partner' is outweighing pure cost comparison in complex modalities such as ADCs, peptides and CGT.